TrialRheumatology (Oxford, England)2020

Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.

Ronald F van Vollenhoven et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.